A-Alpha Bio
Seattle, US · 3 known investors
A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development. The company operates experimental (AlphaSeq) and computational (AlphaBind) platforms to accelerate the design of novel therapeutics.
Founders & leadership
DY
David Younger, PhDChief Executive Officer & Co-Founder
RL
Randolph Lopez, PhDChief Technology Officer & Co-Founder
Investors · 3
In the news
- Sell or Invest in A-Alpha Bio Stock Pre-IPOnasdaqprivatemarket.com · 2025
- A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development - Xontogenyxontogeny.com · 2023
- A-Alpha Bio, a biotech startup that measures and predicts protein interactions, raises $22.4M – GeekWiregeekwire.com · 2023
- A-Alpha Bio - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- A-Alpha Bio - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- A-Alpha Bio Raises $2.8 million in Seed Financing to Develop NGS-Based Protein Interaction Tech | GenomeWebgenomeweb.com · 2019